New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareThymulin vs PNC-27

Thymulin vs PNC-27

Side-by-side comparison of key properties, dosing, and research.

Immune Support
Thymulin
Immune Support
PNC-27
Summary
Thymulin is a nonapeptide hormone produced exclusively by the thymic epithelium. It requires zinc for biological activity and plays a critical role in T-lymphocyte maturation, differentiation, and immune regulation. Thymulin levels decline dramatically with age, contributing to immunosenescence.
PNC-27 is a synthetic peptide derived from the p53 tumor suppressor protein, containing both an HDM2-binding domain and a transmembrane penetratin sequence. It selectively kills cancer cells by binding MDM2/HDM2 overexpressed on the plasma membrane of malignant cells, inducing membranolysis without harming normal cells.
Half-Life
~30 minutes active half-life
Not well established; estimated minutes to hours
Admin Route
SubQ
Intravenous (research), Intraperitoneal (research)
Research
Typical Dose
20-30 mcg
Not established for humans; research doses vary by cell line and model
Frequency
10 days per month (Khavinson protocol)
Not established for human use
Key Benefits
  • Enhances T-cell maturation and differentiation
  • Boosts NK cell cytotoxic activity
  • Reduces inflammatory cytokine production (TNF-α, IL-1)
  • Anti-nociceptive (pain-reducing) properties
  • Restores age-related immune decline
  • Anti-inflammatory via serotonin pathway modulation
  • Selective cytotoxicity against cancer cells overexpressing HDM2/MDM2
  • Spares normal cells lacking surface HDM2 expression
  • Membranolytic mechanism bypasses intracellular resistance pathways
  • Demonstrated activity against breast, pancreatic, leukemia, and melanoma cell lines
  • Potential for combination with conventional chemotherapy
  • Novel non-genotoxic anticancer mechanism
Side Effects
  • Injection site reactions
  • Mild fatigue initially as immune system activates
  • Limited human clinical data; largely in vitro and animal studies
  • Potential immunogenic reactions (foreign peptide)
  • Systemic toxicity at high doses not well characterized
  • Unknown interactions with current chemotherapy agents
Stacks With